1,1-ethylenedioxy-3-[(E)-3-oxo-7-phenyl-1-hepten-1-yl]cyclohexane | 183872-12-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,1-ethylenedioxy-3-[(E)-3-oxo-7-phenyl-1-hepten-1-yl]cyclohexane
• 英文别名: (E)-1-(1,4-dioxaspiro[4.5]decan-7-yl)-7-phenylhept-1-en-3-one
• CAS: 183872-12-0
• 化学式: C₂₁H₂₈O₃
• 分子量: 328.452
• InChiKey: RBONNDSRPHGBDE-OUKQBFOZSA-N

物化性质

• 沸点：
  495.9±40.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,1-ethylenedioxy-3-[(E)-3-oxo-7-phenyl-1-hepten-1-yl]cyclohexane 在 4-甲基苯磺酸吡啶 作用下， 以 水 、 丙酮 为溶剂， 反应 4.0h， 以96%的产率得到3-[(E)-3-oxo-7-phenyl-1-hepten-1-yl]cyclohexanone
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of New 1,3-Disubstituted Cyclohexanes as Structurally Rigid Leukotriene B₄ Receptor Antagonists

  摘要：

  A series of 1-hydroxy-3-[3-hydroxy-7-phenyl-1-hepten-1-yl] cyclohexane acetic acid derivatives was designed based on postulated active conformation of leukotriene B-4 (LTB4) and evaluated as human cell surface LTB4 receptor (BLTR) antagonists. Binding was determined through [H-3]LTB4 displacement from human neutrophils and receptor antagonistic assays by in vitro measurements of inhibition of leukocyte chemotaxis induced by LTB4. On the basis of these assays, a structure-affinity relationship was investigated. Optimization of the acid chain length and omega-substitution of a phenyl group on the lipophilic tail were shown to be critical for binding activity. These modifications led to the discovery of compounds with submicromolar potency and selective BLTR antagonism. The most potent compound 3b alpha (IC50 = 250 nM) was found to significantly inhibit oedema formation in a topical model of phorbolester-induced inflammation. Substantial improvement of in vitro potency was achieved by modification of the carboxylic acid function leading to the identification of the N,N-dimethylamide series. Compound 5b alpha, free of agonist activity, displayed higher potency in receptor binding with an IC50 of 40 nM. These results support the hypothesis that the spatial relationship between the carboxylic acid and allylic hydroxyl functions is crucial for high binding affinity with BLTR.

  DOI：

  10.1021/jm9910573
• 作为产物：
  描述：

  3-羟基环己烷羧酸甲酯 在 chromium(VI) oxide 、 硫酸 、 sodium hydride 、 二异丁基氢化铝 、 APTS 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 1,1-ethylenedioxy-3-[(E)-3-oxo-7-phenyl-1-hepten-1-yl]cyclohexane
  参考文献：
  名称：

  Synthesis and pharmacological profile of new 1,3-disubstituted cyclohexanes as leukotriene B4 receptor antagonists

  摘要：

  In the course of developing stable leukotriene B-4 antagonists, we synthesized a novel non aromatic series of compounds containing a 1, 3-disubstituted cyclohexane ring in place of the conjugated double bonds of the natural eicosanoid. The Structure-Activity Relationship (SAR) studies leading to the identification of the acid <(1d)under bar> are described. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00424-6

文献信息

• Nouveaux composés (cyclohexyl) alcéniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
  申请人：ADIR ET COMPAGNIE

  公开号：EP0611755A1

  公开（公告）日：1994-08-24

  L'invention concerne les composés de formule : dans laquelle R₁, R₂, R₃, R₄, R₅ et B sont tels que définis dans la description, leurs énantiomères et diastéréoisomères, leurs isomères Z et E, et leurs sels d'addition à une base ou à un acide pharmaceutiquement acceptable. Médicaments.

  本发明涉及式： 其中 R₁、R₂、R₃、R₄、R₅ 和 B 如描述中所定义、 它们的对映体和非对映异构体，它们的 Z 和 E 异构体、 以及它们与药学上可接受的碱或酸的加成盐。 药物。
• US5639902A
  申请人：——

  公开号：US5639902A

  公开（公告）日：1997-06-17
• Synthesis and Structure−Activity Relationships of New 1,3-Disubstituted Cyclohexanes as Structurally Rigid Leukotriene B₄ Receptor Antagonists
  作者：Jean-Marc Poudrel、Pierre Hullot、Jean-Pierre Vidal、Jean-Pierre Girard、Jean-Claude Rossi、Agnès Muller、Claude Bonne、Vladimir Bezuglov、Igor Serkov、Pierre Renard、Bruno Pfeiffer

  DOI：10.1021/jm9910573

  日期：1999.12.1

  A series of 1-hydroxy-3-[3-hydroxy-7-phenyl-1-hepten-1-yl] cyclohexane acetic acid derivatives was designed based on postulated active conformation of leukotriene B-4 (LTB4) and evaluated as human cell surface LTB4 receptor (BLTR) antagonists. Binding was determined through [H-3]LTB4 displacement from human neutrophils and receptor antagonistic assays by in vitro measurements of inhibition of leukocyte chemotaxis induced by LTB4. On the basis of these assays, a structure-affinity relationship was investigated. Optimization of the acid chain length and omega-substitution of a phenyl group on the lipophilic tail were shown to be critical for binding activity. These modifications led to the discovery of compounds with submicromolar potency and selective BLTR antagonism. The most potent compound 3b alpha (IC50 = 250 nM) was found to significantly inhibit oedema formation in a topical model of phorbolester-induced inflammation. Substantial improvement of in vitro potency was achieved by modification of the carboxylic acid function leading to the identification of the N,N-dimethylamide series. Compound 5b alpha, free of agonist activity, displayed higher potency in receptor binding with an IC50 of 40 nM. These results support the hypothesis that the spatial relationship between the carboxylic acid and allylic hydroxyl functions is crucial for high binding affinity with BLTR.
• Synthesis and pharmacological profile of new 1,3-disubstituted cyclohexanes as leukotriene B4 receptor antagonists
  作者：J.M. Poudrel、P. Hullot、J.P. Vidal、J.P. Girard、J.C. Rossi、A. Muller、C. Bonne

  DOI：10.1016/0960-894x(96)00424-6

  日期：1996.10

  In the course of developing stable leukotriene B-4 antagonists, we synthesized a novel non aromatic series of compounds containing a 1, 3-disubstituted cyclohexane ring in place of the conjugated double bonds of the natural eicosanoid. The Structure-Activity Relationship (SAR) studies leading to the identification of the acid <(1d)under bar> are described. Copyright (C) 1996 Elsevier Science Ltd